A systematic review of the effectiveness of adalimumab

TABLE 132 Variation 10: TNF inhibitors third (late RA values) (200,000 patients) (cont’d)
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
Comparison ICER (£ per QALY) Quasi-CI
Adal – Base 324,000 265,000 to 417,000
Etan – Base 57,900 56,200 to 59,600
Ad+M – Base 84,600 80,000 to 89,700
Et+M – Base 59,700 57,900 to 61,600
In+M – Base 246,000 210,000 to 296,000
Ad+M – Adal 1,700 1,030 to 2,370
Etan – Et+M Comparison is inconclusive
Etan – Adal 19,400 18,700 to 20,200
Et+M – Ad+M 34,100 32,000 to 36,400
Ad+M – In+M 2,500 1,740 to 3,260
Et+M – In+M 21,300 20,400 to 22,100
TABLE 133 Variation 10: TNF inhibitors last (20,000 patients)
Option Cost (£) QSE QALYs QSE
Adal 35,547 213 1.7509 0.0217
Etan 48,513 259 2.8543 0.0263
Adal+MTX 36,079 215 2.0217 0.0220
Etan+MTX 48,990 261 2.8815 0.0269
Infl+MTX 35,384 203 1.7622 0.0220
Base 2,789 11 0.9214 0.0179
Comparison Diff. cost (£) QSE Diff. QALY QSE
Adal – Base 32,758 211 0.8294 0.0161
Etan – Base 45,724 257 1.9328 0.0226
Ad+M – Base 33,290 213 1.1003 0.0166
Et+M – Base 46,201 259 1.9601 0.0231
In+M – Base 32,594 201 0.8407 0.0162
Ad+M – Adal 532 292 0.2709 0.0202
Et+M – Etan 476 344 0.0273 0.0297
Etan – Adal 12,966 318 1.1034 0.0251
Et+M – Ad+M 12,911 323 0.8598 0.0261
Ad+M – In+M 695 284 0.2596 0.0204
Et+M – In+M 13,606 314 1.1193 0.0258
Comparison ICER (£ per QALY) Quasi-CI
Adal – Base 39,500 37,900 to 41,200
Etan – Base 23,700 23,100 to 24,300
Ad+M – Base 30,300 29,300 to 31,300
Et+M – Base 23,600 23,000 to 24,200
In+M – Base 38,800 37,300 to 40,400
Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant
Et+M – Etan Comparison is inconclusive
Etan – Adal 11,800 11,000 to 12,500
Et+M – Ad+M 15,000 13,900 to 16,300
Ad+M – In+M 2,680 449 to 4,910
Et+M – In+M 12,200 11,400 to 12,900
205